Compounds > succinylglycyl-prolyl-leucyl-glycyl-prolyl-4-methylcoumaryl-7-amide
Page last updated: 2024-12-07

succinylglycyl-prolyl-leucyl-glycyl-prolyl-4-methylcoumaryl-7-amide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID126302
MeSH IDM0081565

Synonyms (17)

Synonym
einecs 276-767-2
4-[[2-[(2s)-2-[[(2s)-4-methyl-1-[[2-[(2s)-2-[(4-methyl-2-oxochromen-7-yl)carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-oxobutanoic acid
72698-36-3
l-prolinamide, n-(3-carboxy-1-oxopropyl)glycyl-l-prolyl-l-leucylglycyl-n-(4-methyl-2-oxo-2h-1-benzopyran-7-yl)-
suc-gly-pro-leu-pro-7-amido-4-methylcoumarin
(succinyl-gly-pro-gly-pro)-4-methylcoumaryl-7-amide
succinylglycyl-prolyl-leucyl-glycyl-prolyl-4-methylcoumaryl-7-amide
n-(3-carboxy-1-oxopropyl)glycyl-l-prolyl-l-leucylglycyl-n-(4-methyl-2-oxo-2h-1-benzopyran-7-yl)-l-prolinamide
suc-gly-pro-leu-gly-pro-amc
mfcd00077163
succinyl-gly-pro-leu-gly-pro-mca
succinyl-gly-pro-leu-gly-pro-4-methylcoumaryl-7-amide
n-suc-gly-pro-leu-gly-pro-amc
suc-gly-pro-leu-gly-pro-mca
4-(2-((s)-2-((s)-4-methyl-1-(2-((s)-2-(4-methyl-2-oxo-2h-chromen-7-ylcarbamoyl)pyrrolidin-1-yl)-2-oxoethylamino)-1-oxopentan-2-ylcarbamoyl)pyrrolidin-1-yl)-2-oxoethylamino)-4-oxobutanoic acid
4-hydroxy-4-{[2-(2-{hydroxy[(1-hydroxy-1-{[2-(2-{hydroxy[(4-methyl-2-oxo-2h-1-benzopyran-7-yl)imino]methyl}pyrrolidin-1-yl)-2-oxoethyl]imino}-4-methylpentan-2-yl)imino]methyl}pyrrolidin-1-yl)-2-oxoethyl]imino}butanoic acid
DTXSID60993520

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" It is concluded that PIP activity dosage in serum may provide with urinary hydroxyproline, further information for the study of collagen metabolism in osteoblastic bone diseases during treatment."( [Determination of serum proline iminopeptidase activity using a fluorescent substrate in patients with Paget's disease and prostatic bone metastases. Preliminary results].
Bouvier, M; Colson, F; Mathieu, M; Tebib, J; Vianey-Liaud, C, 1986)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's2 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.41 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hydroxyproline
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.		1.96104-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		1.9610ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		3.2260benzenes;
hydroxycoumarin;
methyl ketone
ConditionIndicatedRelationship StrengthStudiesTrials
Rheumatoid Arthritis
[description not available]		01.9710
Arthritis, Degenerative
[description not available]		01.9710
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		01.9710
Osteoarthritis
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.		01.9710
Bone Cancer
[description not available]		01.9610
Osseous Paget's Disease
[description not available]		01.9610
Cancer of Prostate
[description not available]		01.9610
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		01.9610
Osteitis Deformans
A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry.		01.9610
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		01.9610